Background: Use of biologicals such as Rituximab (RTX) in Rheumatoid Arthritis (RA) is effective and often only licensed in combination with Methotrexate (MTX). In cases of contraindications to or intolerances of MTX other cDMARDs are frequently used without robust data from RCTs. In addition, different strategies of retreatment of RTX are available. Objectives: To demonstrate efficacy on patient-reported outcomes (PROs) of RTX in combination with leflunomide (LEF) in a multicenter investigator-initiated placebo (PLA)-controlled RCT in Germany. Methods: A total of 189 patients with active RA (DAS28>3.2 and at least 3 SJC and 3 TJC) despite stable LEF treatment were screened for a 52-weeks double-blind placebo controlled RCT. Patients were randomized to receive either
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